A new trial finds that intravenous immunoglobulin stabilises kidney function and slows damage in patients with chronic ...

Therapeutic plasma exchange combined with intravenous immunoglobulin reduced biological age on average by 2.6 years, as ...

Dr. Ananda Wijewickrama, Chairman of the National Medicines Regulatory Authority (NMRA), has affirmed that there are no ...

The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin ...

The Ministry of Health has clarified recent reports concerning the immunoglobulin drug manufactured by India’s ICHOR ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

Despite the well-recognized involvement of immunoglobulin (Ig) A in mucosal immunity, the function of its receptor, FcαRI (CD89), is poorly understood. The ability of FcαRI to activate ...

Due to the autoimmune etiology of this disorder, IV immunoglobulin (IVIg) or plasma exchange (PE) are the first-line treatments in addition to management of ventilatory failure. IVIg is more ...

By binding and inhibiting APRIL, sibeprenlimab may help reduce the amount of immunoglobulin A (IgA) and Gd-IgA1 levels. Lower levels of Gd-IgA1 provide less substrate for immune complex formation ...

The immunoglobulin medication currently in use in Sri Lanka meets proper quality standards, confirmed National Medicines Regulatory Authority (NMRA) Chairman Dr. Ananda Wijewickrama in a statement ...